SCHEMBL350408

SCHEMBL350408

ON1CCOCC1c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.42
BACE1 P56817 1/20 0.41
PIK3C3 Q8NEB9 2/20 0.41
NR3C2 P08235 2/20 0.40
RIPK1 Q13546 1/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
SCD5 Q86SK9 1/20 0.39
TSHR P16473 2/20 0.38
ATM Q13315 1/20 0.38
LMNA P02545 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
HDAC6 Q9UBN7 3/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16130557 0.78 CHRNB2 (0.55) NUDT1BACE1PIK3C3NR3C2MEN1
SCHEMBL18713207 0.78 NUDT1 (0.42) NUDT1BACE1PIK3C3NR3C2RIPK1
SCHEMBL2606087 0.78 CHRNB2 (0.55) NUDT1BACE1PIK3C3NR3C2MEN1
SCHEMBL16130585 0.78 CHRNB2 (0.55) NUDT1BACE1PIK3C3NR3C2MEN1
SCHEMBL13104784 0.77 P2RX7 (0.43) NUDT1BACE1PIK3C3NR3C2RIPK1
SCHEMBL15273881 0.77 P2RX7 (0.43) NUDT1BACE1PIK3C3NR3C2RIPK1
SCHEMBL27364822 0.77 BACE1 (0.53) BACE1PIK3C3NR3C2RIPK1SCD5
SCHEMBL14829587 0.77 BACE1 (0.53) BACE1PIK3C3NR3C2RIPK1POLB
Bromide SCHEMBL5224743 0.76 CHRNB2 (0.53) NUDT1BACE1PIK3C3NR3C2MEN1
SCHEMBL27331726 0.76 NR3C2 (0.54) NUDT1PIK3C3NR3C2LMNAHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015947-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2012-01-19 US disclosed
US-20120015947-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2012-01-19 US disclosed
US-20120015947-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2012-01-19 US disclosed
US-8053432-B2 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2011-11-08 US disclosed
US-8053432-B2 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2011-11-08 US disclosed
US-8053432-B2 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2011-11-08 US disclosed
US-7842690-B2 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2010-11-30 US disclosed
US-7842689-B2 suitable for the treatment of anxiety and depression; 2-(4-hydroxymorpholin-3-yl)cyclohex-2-en-1-one; anxiolytic agents; antidepressants BTG INTERNATIONAL LIMITED (GB) 2010-11-30 US disclosed
US-7842689-B2 suitable for the treatment of anxiety and depression; 2-(4-hydroxymorpholin-3-yl)cyclohex-2-en-1-one; anxiolytic agents; antidepressants BTG INTERNATIONAL LIMITED (GB) 2010-11-30 US disclosed
US-7842689-B2 suitable for the treatment of anxiety and depression; 2-(4-hydroxymorpholin-3-yl)cyclohex-2-en-1-one; anxiolytic agents; antidepressants BTG INTERNATIONAL LIMITED (GB) 2010-11-30 US disclosed
CN-1805944-B Cyclic hydroxylamine as psychoactive compounds BRITISH TECH GROUP INT 2010-06-16 CN disclosed
US-20090312329-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2009-12-17 US disclosed
US-20090312329-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2009-12-17 US disclosed
US-20090312329-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2009-12-17 US disclosed
EP-1631557-B1 CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS BTG INT LTD (GB) 2006-12-20 EP disclosed
CN-1805944-A Cyclic hydroxylamine as psychoactive compounds BTG INT LTD (GB) 2006-07-19 CN disclosed
US-20060142286-A1 Cyclic hydroxylamine as psychoactive compounds BTG INTERNATIONAL LIMITED (GB) 2006-06-29 US disclosed
EP-1631557-A1 CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS BTG INTERNATIONAL LIMITED (GB) 2006-03-08 EP disclosed
WO-2004111021-A1 CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS BTG INTERNATIONAL LIMITED (GB) 2004-12-23 WO disclosed
WO-2004111021-A1 CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS BTG INTERNATIONAL LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015947-A1 Cyclic hydroxylamine as psychoactive compounds HTR1A, HTR1D, OPRM1 NUDT1 1706/4885BACE1 3611/4885PIK3C3 4615/4885
US-20090312329-A1 Cyclic hydroxylamine as psychoactive compounds HTR1A, HTR2C, OPRM1 NUDT1 1491/4885BACE1 3466/4885PIK3C3 4498/4885
US-20060142286-A1 Cyclic hydroxylamine as psychoactive compounds HTR1A, HTR2C, OPRM1 NUDT1 1491/4885BACE1 3466/4885PIK3C3 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.